CA3174316A1 - Inhibiteur cristallin de ret - Google Patents

Inhibiteur cristallin de ret Download PDF

Info

Publication number
CA3174316A1
CA3174316A1 CA3174316A CA3174316A CA3174316A1 CA 3174316 A1 CA3174316 A1 CA 3174316A1 CA 3174316 A CA3174316 A CA 3174316A CA 3174316 A CA3174316 A CA 3174316A CA 3174316 A1 CA3174316 A1 CA 3174316A1
Authority
CA
Canada
Prior art keywords
selpercatinib
acid
slurry
cancer
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3174316A
Other languages
English (en)
Inventor
Rajni Miglani BHARDWAJ
Mark Steven Kerr
Douglas Patton Kjell
Jeremy Miles MERRITT
Jon Gordon Selbo
Shekhar Krishna VISWANATH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Loxo Oncology Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3174316A1 publication Critical patent/CA3174316A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La présente invention concerne une forme cristalline de selpercatinib utile dans le traitement et la prévention de maladies qui peuvent être traitées avec un inhibiteur de kinase RET, y compris des maladies et des troubles associés à RET, et des procédés de production de cette forme cristalline.
CA3174316A 2020-04-17 2021-04-09 Inhibiteur cristallin de ret Pending CA3174316A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063011701P 2020-04-17 2020-04-17
US63/011,701 2020-04-17
US202163151354P 2021-02-19 2021-02-19
US63/151,354 2021-02-19
PCT/US2021/026611 WO2021211380A1 (fr) 2020-04-17 2021-04-09 Inhibiteur cristallin de ret

Publications (1)

Publication Number Publication Date
CA3174316A1 true CA3174316A1 (fr) 2021-10-21

Family

ID=75747118

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3174316A Pending CA3174316A1 (fr) 2020-04-17 2021-04-09 Inhibiteur cristallin de ret

Country Status (17)

Country Link
EP (1) EP4136090A1 (fr)
JP (1) JP2023522012A (fr)
KR (1) KR20230002706A (fr)
CN (1) CN115916791A (fr)
AU (1) AU2021255488A1 (fr)
BR (1) BR112022020446A2 (fr)
CA (1) CA3174316A1 (fr)
CL (1) CL2022002849A1 (fr)
CO (1) CO2022014882A2 (fr)
CR (1) CR20220520A (fr)
DO (1) DOP2022000221A (fr)
EC (1) ECSP22080982A (fr)
IL (1) IL297212A (fr)
MX (1) MX2022012952A (fr)
PE (1) PE20230388A1 (fr)
TW (1) TW202202501A (fr)
WO (1) WO2021211380A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022069357A1 (fr) * 2020-10-01 2022-04-07 Sandoz Ag Forme cristalline du selpercatinib
WO2023114119A1 (fr) 2021-12-13 2023-06-22 Loxo Oncology, Inc. Procédés de préparation de la forme cristalline a du selpercatinib, inhibiteur de ret

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI704148B (zh) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI812649B (zh) * 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI783057B (zh) 2017-10-10 2022-11-11 美商絡速藥業公司 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法
EP3845531A4 (fr) * 2018-09-30 2021-11-24 Applied Pharmaceutical Science, Inc. Dérivé cyclique condensé à un pyrazole substitué, son procédé de préparation et application associée
CN111004257B (zh) * 2019-12-24 2021-06-29 武汉九州钰民医药科技有限公司 制备RET抑制剂Selpercatinib的方法

Also Published As

Publication number Publication date
TW202202501A (zh) 2022-01-16
BR112022020446A2 (pt) 2022-11-29
JP2023522012A (ja) 2023-05-26
PE20230388A1 (es) 2023-03-06
CN115916791A (zh) 2023-04-04
DOP2022000221A (es) 2023-01-15
CR20220520A (es) 2022-11-15
CO2022014882A2 (es) 2022-10-31
IL297212A (en) 2022-12-01
KR20230002706A (ko) 2023-01-05
MX2022012952A (es) 2023-01-11
ECSP22080982A (es) 2023-01-31
WO2021211380A1 (fr) 2021-10-21
CL2022002849A1 (es) 2023-06-16
AU2021255488A1 (en) 2022-11-10
EP4136090A1 (fr) 2023-02-22

Similar Documents

Publication Publication Date Title
CN114846006A (zh) 杂环化合物及其制备方法和用途
KR20090061055A (ko) 결정질 및 비결정질 이매티닙 염기, 이매티닙 메실레이트 및 이들의 제조 방법
CA3174316A1 (fr) Inhibiteur cristallin de ret
US10550101B2 (en) Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof
TW201629060A (zh) 一種週期素依賴性蛋白激酶抑制劑的羥乙基磺酸鹽、其結晶形式及製備方法
TW202112768A (zh) 二取代吡唑化合物
EP3665176B1 (fr) Formes solides de 3-(5-fluorobenzofuran-3-yl)-4-(5-méthyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
US20230212193A1 (en) Crystalline ret inhibitor
CN113461670A (zh) 作为转染期间重排激酶抑制剂的新的化合物
US20220372019A1 (en) Salts and solid state forms of plinabulin
KR20180086508A (ko) 치환된 5,6-디하이드로-6-페닐벤조[f]이소퀴놀린-2-아민 화합물의 고체 형태
EP4361153A1 (fr) Nouveau composé hétérocyclique bifonctionnel ayant une fonction de dégradation de btk par l'intermédiaire d'une voie de protéasome d'ubiquitine, et son utilisation
CN117729921A (zh) 作为pd1/pd-l1抑制剂的化合物及其方法
EP3988551A1 (fr) Inhibiteur de kinase cdk
CN113840605A (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺及其盐的结晶和无定形形式，及其制备方法和治疗用途
US20230183266A1 (en) Crystalline forms of ret inhibitor and preparation thereof
EP3960742A1 (fr) Cristaux de composé contenant un alcynyle, sel et solvate de celui-ci, procédé de préparation et utilisations
WO2022206666A1 (fr) Forme cristalline d'un composé de pyrrole amide, son procédé de préparation et son utilisation
WO2023116895A1 (fr) Polymorphe d'inhibiteur de kras, son procédé de préparation et son utilisation
CN111377934B (zh) 一类杂环化合物，其制备及用途
WO2022033563A1 (fr) Composé inhibiteur de jak et son utilisation
US20230373998A1 (en) Solid state forms of lorecivivint
WO2023138681A1 (fr) Sel d'acide ou forme cristalline d'inhibiteur de dérivé à cycle condensé contenant de l'azote, son procédé de préparation et son utilisation
EP4169915A1 (fr) Forme cristalline de composé
CN111484489B (zh) 无定形的b-raf激酶二聚体抑制剂

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929